EZH2 is a promising therapeutic target for many different types of cancer36, and our results show that EZH2 inhibitors have the potential to restore PTEN expression, which may present therapeutic benefit in breast cancer patients with NOTCH alterations. This evidence concerns the gene PTEN and breast cancer.